Download Free Medical Thyroid Neoplasms PowerPoint Presentation

Thyroid Neoplasms PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Endocrine Surgery, which is titled "Thyroid Neoplasms", to know about Thyroid Neoplasms.

Tags : Endocrine Surgery, Thyroid Neoplasms

Published on : Jul 20, 2021 | Views : 3513 | Downloads : 8

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Thyroid Neoplasms Dr. Amit Gupta Associate Professor Dept. of Surgery
Slide 2-

Introduction Six deaths per 1 million people occur annually. Occurs in about 40 per 1 million people per year The most common endocrine malignancy Accounts for 95% of all endocrine cancers Female to Male Ratio 2.5:1
Slide 3-

Thyroid Neoplasms Primary Tumours Epithelial Malignant Lymphomas Mesenchymal tumours Metastatic Tumours
Slide 4-

Epithelial Thyroid Neoplasms Tumours of follicular cells Benign (adenomas) Follicular adenoma Malignant (carcinomas) Follicular carcinoma (10-20%) Papillary carcinoma (75-85%) Undifferentiated (anaplastic) carcinoma (<5%) Tumours of C-cells Medullary thyroid carcinoma (MTC - 5%)
Slide 5-

Risk Factors for Thyroid Cancer The only well-established risk factor for differentiated thyroid cancer is head and neck Radiation,especially during infancy Papillary thyroid carcinoma may occur in several rare inherited syndromes, including familial adenomatous polyposis, Gardner's syndrome, and Cowden's disease Patient’s Age and Gender Malignancy more common in children and adults >60 Men
Slide 6-

Follicular Carcinoma Second most common form, 10-20% Females > Males, average age = 45 - 55 yr Rare in children Solitary nodule, painless, cold on isotopic scan 50% 10 yr survival Vs 90%10 yr survival Haematogenous route is preferred mode of spread
Slide 7-

Follicular Carcinoma Solitary round or oval nodule Thick capsule Composed of follicles Capsular invasion or vascular invasion within or outside capsular wall
Slide 8-

Papillary Carcinoma Commonest thyroid malignancy, 75-85% Female:Male = 2.5:1 Mean age at onset = 20 - 40 yr May affect children Prior head & neck radiation exposure Indolent, slow-growing painless mass cold on isotopic scan Cervical lymphadenopathy may be presenting feature
Slide 9-

Papillary Carcinoma Variable size (microscopic to several cm) Solid or cystic Infiltrative or encapsulated Solitary or multicentric (20%)
Slide 10-

Papillary Carcinoma Nuclear Features Optically clear (ground glass, Orphan Annie) nuclei Nuclear pseudoinclusions or nuclear grooves
Slide 11-

Papillary Carcinoma Prognosis Excellent but following factors play important role: Age and sex Size Multicentricity Extra-thyroid extension Distant metastasis Total encapsulation, pushing margin of growth & cystic change
Slide 12-

Anaplastic Carcinoma Rare; < 5% of thyroid carcinomas Highly malignant and generally fatal < 1yr. Elderly 65 yrs; females slightly > males Rapidly enlarging bulky neck mass Dysphagia, dyspnoea, hoarseness
Slide 13-

Anaplastic Carcinoma Large, firm, necrotic mass Frequently replaces entire thyroid gland Extends into adjacent soft tissue, trachea and oesophagus Highly anaplastic cell on histology with: Giant, spindle,small or mix cell population Foci of papillary or follicular differentiation
Slide 14-

Anaplastic Carcinoma Cellular pleomorphism +/- multinucleated giant cells High mitotic activity Necrosis
Slide 15-

Medullary Thyroid Carcinoma (MTC) Malignant tumour of thyroid C cells producing Calcitonin 5 % of all thyroid malignancies Sporadic (80%) Rest in the setting of MEN IIA or B or as familial without associated MEN syndrome
Slide 16-

Medullary Thyroid Carcinoma (MTC) Sporadic MTC Middle-aged adults Female:male = 1.3:1 Unilateral involvement of gland +/- cervical lymph node metastases Indolent course with 60-70% 5-yr survival after thyroidectomy
Slide 17-

Multiple Endocrine Neoplasia Types IIA & IIB Germ-line mutation in Ret protooncogene on chromosome 10q11.2 MEN IIA: MTC, phaeochromocytoma, parathyroid adenoma or hyperplasia MEN IIB: MTC, phaeochromocytoma, mucosal ganglioneuromas, Marfanoid habitus, other skeletal abnormalities
Slide 18-

Medullary Thyroid Carcinoma (MTC) Histology same for sporadic & familial Solid, lobular or insular growth patterns Tumour cells round, polygonal or spindle-shaped Amyloid deposits in many cases
Slide 19-

Medullary Thyroid Carcinoma (MTC) Amyloid deposits stain orange-red with Congo Red stain
Slide 20-

Clinical Manifestation Most patients are euthyroid and present with a thyroid nodule Symptoms such as dysphagia, dyspnea and hoarseness usually indicate advanced disease Ipsilateral Cervical lymph glands may also be present.
Slide 21-

Diagnosis Serum TSH Fine Needle Aspiration Cytology (FNA) High Resolution Thyroid US- helpful in detecting non palpable nodule and solid versus cystic lesion Thyroid Isotope Scanning- to assess functional activity of a nodule
Slide 22-

Fine Needle Aspiration Procedure of Choice – Fast, minimally invasive and few risk Incidence of False positive: 1% Incidence of False negative: 5% FNA is not a tissue diagnosis Limitation of FNA: cannot distinguish a benign follicular from a malignant lesion.
Slide 23-

FNA Results of Thyroid Nodule
Slide 24-

ppt slide no 24 content not found
Slide 25-

Staging For Differentiated Thyroid Cancer In differentiated thyroid carcinoma, several classification and staging systems have been introduced. However, no clear consensus has emerged favoring any one method over another AMES system/AGES System/GAMES system TNM system MACIS system National Thyroid Cancer Treatment Cooperative Study (NTCTCS)
Slide 26-

Prognosis GAMES scoring (Papillary & Follicular Cancer) G Grade A Age of patient when tumor discovered M Metastases of the tumor (other than Neck LN) E Extent of primary tumor S Size of tumor (>5 cm) The patient is then placed into a high or low risk Category Age for poor prognosis has been raised from 45 to 55 years (AJCC 8th Edition)
Slide 27-

(GAMES)
Slide 28-

Prognosis of Thyroid Carcinomas Papillary Best prognosis Follicular Medullary Anaplastic Worst prognosis
Slide 29-

Hürthle Cell Neoplasms More aggressive than other differentiated thyroid carcinomas (higher mets/lower survival rates) Decreased affinity for I131 Need to differentiate from benign/malignant 65% of tumors > 4cm are malignant If malignant, needs total thyroidectomy and I131 with thyroglobulin assays Mets may be more sensitive to I131 than primary
Slide 30-

Secondary Tumours Direct extensions from: larynx, pharynx, oesophagus Metastasis from: renal cell carcinoma, large bowel carcinoma, malignant melanoma, lung carcinoma, breast carcinoma
Slide 31-

Treatment The main treatment of papillary carcinoma of the thyroid is surgical resection. For lesions <1 cm, there is general agreement in the literature that lobectomy plus isthmectomy is the appropriate treatment. For adults with lesions larger than 2 cm, a total thyroidectomy is favored by most surgeons. Patients with history of exposure to ionizing radiation of the head and neck should have total thyroidectomy
Slide 32-

Controversies in Treatment Total Vs Lobectomy Controversy exists about the use of total thyroidectomy versus lobectomy and isthmectomy in adults with a 1- to 2-cm lesions Role of Lymph node dissection also debated
Slide 33-

Central Lymph Node Dissection Central compartment =the region bounded by the jugular veins, the hyoid bone, and the sternal notch All central nodes removed at time or procedure Removal of Central Nodes important in medullary and Hurthle Cell Ca Microscopic spread is high Do not take up I131 and cannot be ablated
Slide 34-

Lateral Lymph Node Dissection Diseased nodes lateral to the jugular vein =modified radical neck dissection Removal of LN’s anterior and posterolateral to the IJV from the mastoid to the subclavian vessels inferiorly and laterally to spinal accessory nerve (Level 2-5) Sparing the internal jugular vein, spinal accessory nerve, and sternocleidomastoid muscle
Slide 35-

Treatment
Slide 36-

Complications of Surgery Hypocalcemia -devascularization of parathyroid about 5%, which resolves in 80% of these cases in about 12 months Recurrent Laryngeal Nerve Injury-either traction induced or division. less than 3% Bleeding wound hematomas
Slide 37-

Postoperative management forthyroid cancer Two principles: Radioiodine remnant ablation Adminstration of Thyroid Hormone To suppress TSH and growth of any residual thyroid To maintain patient euthyroid Maintain TSH level 0.1uU/ml in low risk pts Maintain TSH Level < 0.1uU/ml in high risk pts
Slide 38-

Postoperative RAI Recommendations: Postoperative remnant ablation for all patients with differentiated thyroid carcinoma 45 years of age or older Those with primary tumor 1.5 cm in diameter or more Extrathyroidal disease, whether manifested by direct invasion through the capsule of the gland or local or regional metastases.
Slide 39-

ppt slide no 39 content not found
Slide 40-

Radioiodine therapy The nonsurgical treatment for papillary thyroid carcinoma is radioiodine (131-I). Radioiodine has three uses in the postoperative treatment of patients with thyroid cancer: ablation of residual thyroid tissue imaging for possible recurrent disease treatment of residual or recurrent thyroid cancer
Slide 41-

External Beam Radiotherapy andChemotherapy External Radiation required to control unresectable cancer. Chemotherapy may occasionally be beneficial in patients with progressive symptomatic thyroid carcinoma that is unresponsive or not amenable to surgery, radioiodine therapy, or external radiotherapy